PDS Biotechnology Corporation (PDSB) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Greetings and welcome to the PDS Biotech fourth quarter 2025 earnings call. At this time, all participants are in listen-only mode. A question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Mike Moyer, with LifeSci Advisors. Thank you. You may begin. Thank you, operator. Good morning, everyone, and welcome to PDS Biotech's fourth quarter 2025 results and clinical programs update call. I'm joined on a call today by the following members of the company's management team. Dr. Frank Badu-Addo, Chief Executive Officer, Dr. Kirk Shepard, Chief Medical Officer, and Lars Bosgaard, Chief Financial Officer. Dr. Badu-Addo will begin with an overview of the company's recent highlights in its clinical development program. Dr. Shepard will review the data and rationale behind the amendment the company recently adopted to its Phase III Versatile 003 trial, and Mr. Bosgaard will review The financial results for the quarter ended December 31st, 2025. Following management's prepared remarks, we will open the call to questions from covering analysts. As a reminder, during this call, we will be making forward-looking statements which are subject to various risks and uncertainties that could cause our actual results to differ materially from these statements. Any such statement should be considered in conjunction with cautionary statements in our press releases. and risk factors discussed in our filings with the SEC, including our quarterly reports on Form 10-Q and annual report on Form 10-K, and cautionary statements made during this call. We assume no obl...